Research programme: human monoclonal antibodies - Medarex/Trillium Therapeutics Inc

Drug Profile

Research programme: human monoclonal antibodies - Medarex/Trillium Therapeutics Inc

Alternative Names: Fgl2 Mab; Fgl2-specific monoclonal antibody

Latest Information Update: 12 Feb 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex; Trillium Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Immunological disorders; Transplant rejection

Most Recent Events

  • 12 Feb 2013 Discontinued - Preclinical for Immunological disorders in USA (unspecified route)
  • 12 Feb 2013 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 03 May 2007 No development reported - Preclinical for Immunological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top